K. Tucker Andersen
Chairman of the Board
K. Tucker Andersen is a retired portfolio manager and securities analyst and the sole proprietor of the consulting firm Above All Advisors, LLC. He previously was co-Managing Partner and Chief Investment Strategist for Cumberland Associates.
Mr. Andersen serves on the boards of the International Foundation for Research in Experimental Economics, the Questech Corporation, the Foundation for the Advancement of Monetary Education, and Pericor Therapeutics, He is also on the advisory boards of Brook Venture Partners and the Lyme Timber Company.
Tucker is currently a trustee of Wesleyan University. While retired from his position as vice-president of the board of the Phillips Exeter Academy, he still serves as a member of Exeter’s investment committee which he formerly chaired.
He received his Bachelor’s in Quantitative Studies from Wesleyan University, and is a recipient of Wesleyan’s Distinguished Alumnus Award and of the Founder’s Day Award from Exeter.
Mr. Andersen is a Chartered Financial Analyst and Associate Member of the Society of Actuaries.
Donald S. Masters, Ph.D.
Board member and and Chief Executive Officer
Dr. Masters is President and Chief Executive Officer of Artificial Cell Technologies. His thirty-eight year career began as a member of the Harvard-Monsanto Project that led to the development of the Biotechnology industry. He left Harvard to become the fifth employee at Genzyme, creating their successful Research Biologicals business unit which was eventually sold for $67 million. He left Genzyme to become the founding CEO of OxiGene, which is now a public company. Following his tenure at OxiGene he became involved in the information technology field, heading up the Biological Applications Program at TASC, Inc. a $300 million per year information technology company, and TechEx a B2B exchange connecting University technology transfer offices to pharmaceutical companies which he successfully sold in 2002. After a period as a Principal at Commonwealth Pharmaceutical Partners, a business development consultancy and affiliate of the Medical Science Partners venture capital fund, he returned to the Biotech CEO ranks, heading up three start-ups: Bion, Inc, C3 Scientific Corporation and Esperance Pharmaceuticals. Dr. Masters became CEO in July of 2008.
Dr. Masters graduated from The Johns Hopkins University with a degree in Biophysics, received his Ph.D. in Biochemistry and Immunology from Cornell University Medical College and was a Post-doctoral Fellow at Harvard Medical School.
Donald T. Haynie, Ph.D.
Don Haynie has a PhD in biophysics from Johns Hopkins University, where he was an NIH pre-doctoral fellow. He was then an NSF post-doctoral research fellow at Oxford University, where he worked with Christopher Dobson, FRS, then Deputy Director of Oxford Centre for Molecular Sciences and currently Professor of Chemistry and Master of St John’s College, Cambridge University. He has held faculty positions in departments of biomolecular sciences, biomedical engineering and physics, and adjunct faculty positions in departments of chemistry and surgery. He was a faculty affiliate of the Institute for Micromanufacturing at Louisiana Tech, where he was principal investigator of a $2.2 million multi-university research consortium in biotechnology. His research has been sponsored by AFOSR, NSF, NIH, NASA, private companies and other sources. He has over 90 peer-reviewed research articles, reviews and conference abstracts to his credit. He is founder of two US biotechnology companies, Artificial Cell Technologies, Inc. (New Haven, CT) and BioLaminex, Inc. (Tampa, FL), and an inventor on 16 issued and licensed US patents. He is author of the best-selling textbook, Biological Thermodynamics, published by Cambridge University Press and in the second edition since 2008. The PI joined the Department of Physics at USF in 2009. He is a member of the Center for Integrated Functional Materials and an associate member of the Nanotechnology Research and Education Center at USF. He was admitted to the USF Academy of Inventors in 2009 and the National Academy of Inventors in 2010. He received USF’s Innovator of the Year Award in 2010.
Dr. Robert S. Langer. DSc
Key Scientific Advisor
Robert S. Langer is one of 14 Institute Professors at the Massachusetts Institute of Technology (MIT). Dr. Langer has written over 1,000 articles and has more than 600 issued or pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.
Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators world wide who will reinvent our future. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best).
Dr. Langer has received honorary doctorates from Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, the Pennsylvania State University, Northwestern University and Uppsala University (Sweden).
He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.